Why more companies are focusing their clinical trials on Bulgaria and Eastern Europe

Clinical trials are one of the most dynamic areas in medicine. They are the engine of innovation - making new therapies reach patients faster and safer. However, much of the global research is concentrated in a limited number of countries in Western Europe and North America, while Eastern Europe remains a largely undervalued region with outstanding potential.

What makes the region so suitable for clinical trials

Bulgaria and the neighbouring countries have all the key elements needed for successful research - well-trained and experienced researchers, modern medical infrastructure, highly qualified medical staff and a stable regulatory framework in line with European standards.

In addition, there is significant potential for patient recruitment in the region. This is often a critical factor in the success of a study, especially in rarer diseases where access to motivated participants is crucial. Observations from our experience are that Bulgarian patients exhibit a high level of engagement and trust in medical professionals, a factor that contributes to the quality and timeliness of studies.

Economic advantage for sponsors

Compared to the busier and more costly markets of Western Europe, conducting clinical trials in Bulgaria and the region offers significantly better value for money. Costs for logistics, monitoring, staffing and medical services are lower without affecting the quality or regulatory rigour of the process.

This enables sponsors to optimize their budget by simultaneously increasing the number of patients enrolled and the conversion rate.

Benefits for patients too

Equally important, participation in clinical trials gives Bulgarian patients access to cutting-edge therapies, often years before they appear on the market. This creates real benefits for the healthcare system and for the individual - especially for diseases for which there are currently no effective therapies.

It is time for the region to take its place

Eastern Europe is not just an alternative location for clinical trials, but a logical, strategic opportunity for sponsors seeking quality, efficiency and partnership. Earning the trust of multiple global sponsors, centres such as Unimed is already proving that the region has the experience, capacity and professionalism to conduct high quality international studies.